...
机译:MTOR激酶抑制剂Everolimus协同增强了Bruton的酪氨酸激酶(BTK)抑制剂PLS-123对搭式细胞淋巴瘤的抗肿瘤作用
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of;
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of;
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of;
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of;
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of;
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of;
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of;
Key Laboratory of Chemical GenomicsSchool of Chemical Biology and Biotechnology Peking University;
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of;
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of;
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of;
Mantle cell lymphoma; BTK inhibitor; mTOR inhibitor; targeted therapy; drug combination;
机译:MTOR激酶抑制剂Everolimus协同增强了Bruton的酪氨酸激酶(BTK)抑制剂PLS-123对搭式细胞淋巴瘤的抗肿瘤作用
机译:Bruton Tyrosine激酶(BTK)抑制剂PCI-32765协同增加弥漫性大B细胞淋巴瘤(DLBCL)和搭腔细胞淋巴瘤(MCL)细胞敏感或耐硼脲(Vol 161,PG 43,2013)中的蛋白酶体抑制剂活性
机译:布鲁顿酪氨酸激酶(BTK)抑制剂PCI-32765协同增加对硼替佐米敏感或耐药的弥漫性大B细胞淋巴瘤(DLBCL)和套细胞淋巴瘤(MCL)细胞中的蛋白酶体抑制剂活性
机译:CNX-774,Bruton的酪氨酸激酶的不可逆转,选择性和口服生物可利用的抑制剂:体外Adme,选择性和药代动力学性能
机译:靶向蛋白质酪氨酸激酶的RNAi筛选可将布鲁顿酪氨酸激酶(BTK)识别为乳腺癌细胞生存因子。
机译:布鲁顿酪氨酸激酶抑制剂CC-292在套细胞淋巴瘤中显示活性并与来那度胺和NIK抑制剂协同作用具体取决于核因子-κB突变状态
机译:用Bruton酪氨酸激酶(BTK)抑制剂Zanubrutinib(BGB-3111)治疗的术术术术(MCL)患者的第1阶段的安全性和疗效数据